The Women's Screening and Self-Testing Program (PROMETA) Study
Recruiting · NCT06810739 · Interventional (participants receive a specific treatment) · Lead sponsor: Tulane University
View the official record on ClinicalTrials.gov →Interventions studied
HPV DNA testing be self-collected vaginal swab
What this trial is about
This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (HIV) care and treatment services. The primary outcome of interest is the number of women screened and the proportion of screen-positive women undergoing treatment. Secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across Mozambique.
Who can take part
Age range
25 Years to 49 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Women 25-49 years
- Accessing HIV care and treatment services
- Not being pregnant
- Patients with a cervix
Exclusion criteria
- Physical or mental impairment that inhibits participation in the study
- Pregnant women or \<6 weeks post-partum
- Women who have undergone a total hysterectomy with removal of the cervix
Where it is running
1 location listed.
- University Eduardo Mondlane (UEM) - Maputo, Mozambique